As the BTKi landscape continues to expand and evidence increasingly supports their use across frontline and high-risk settings, clinicians must be prepared to appropriately select therapies, interpret emerging efficacy and safety data, and proactively manage treatment-related toxicities in older and medically complex veteran populations. This professional education activity will provide clear, balanced, and evidence-based review of BTKi mechanisms of action, clinical trial outcomes, and real-world considerations for individualized treatment planning and adverse-event management. Learning outcomes from this activity are intended to support informed clinical decision-making and ultimately optimize outcomes for veterans with MCL treated within the VHA healthcare system.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Address:
- 384 Inverness Parkway
Pricing
All courses included · from $18.75/mo
Courses are included in the subscription; some are also sold individually.
| Student Flex | $18.75/mo |
| Professional Flex | $60/mo |
| Student 3-Year | $100 |
| Student 2-Year | $112.50 |
+4 more plans
Collected from the provider’s public pages · source
Specialties served/covered
- Cardiovascular Disease
- Communication & Shared Decision-Making
- Dermatology
- Endocrinology, Diabetes & Metabolism
- Family Medicine
- Gastroenterology
- Gastrointestinal Surgery
- General & Adult Psychiatry
- General Internal Medicine
- Gynecologic Oncology
- Health Equity & Inclusion
- Hematology
- Maternal-Fetal Medicine
- Medical Leadership & Administration
- Medical Oncology
- Mood & Anxiety Disorders
- Nephrology
- Neurocritical Care
- Neurodevelopmental Disabilities
- Neurology
- Neuroradiology
- Nuclear Medicine
- Obstetrics & Gynecology
- Ophthalmology
- Plastic & Reconstructive Surgery
- Practice Management & Ethics
- Pulmonary Disease
- Sleep Medicine
- Surgical Oncology
- Thoracic Anesthesia
- Urological Oncology
- Anesthesiology
- Cardio-Vascular
- Cross-Specialty
- Emergency & Critical Care
- GI & Liver
- Infectious Disease
- Internal Medicine
- Medical Subspecialties
- Neurology
- Ob/Gyn
- Oncology & Hematology
- Primary care
- Psychiatry
- Radiology
- Surgery
- Urology
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- Live
- Credit · Up to 1 credit
- Commercial Support
-
WhenAug 17 – Dec 31, 2026
-
Plexus Communications +1 Advancing Frontline Therapy in Mantle Cell Lymphoma: The Evolving Role of BTK Inhibitors
-
Plexus Communications +1 Advancing Metastatic NSCLC: The Role of HER2- and TROP2-Targeted Antibody-Drug Conjugates
-
Plexus Communications +1 Pathways to Practice Change: Leveraging Advances in BTKi-Based Treatment Regimens for Veterans with Chronic Lymphocytic Leukemias
-
Efficient CME, CME Outfitters, LLC Evidence in Action: Using Expert Insights and Practice Patterns to Guide Optimal Treatment of Chronic Lymphocytic Leukemia
-
Creative Educational Concepts, Inc. AI-Powered Precision Learning: Optimizing Frontline Treatment Decision-Making in Chronic Lymphocytic Leukemia: Integrating Biomarkers, Clinical Evidence, and Patient-Centered Care
-
PVI, PeerView Institute for Medical Education Navigating Frontline CLL Care With Modern BTKi and BCL2i Strategies: Rising to the Global Challenge
